Sabarubicin

Drug Profile

Sabarubicin

Alternative Names: BMS 195615; MEN-10755

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Menarini
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 09 Sep 2015 No recent reports on development was identified - Phase-II for Solid tumours in Europe (IV)
  • 03 Jun 2008 Final efficacy and adverse event data from a phase II trial in Small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 04 Sep 2007 Phase II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top